Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
pos +0.00
Today's Range: 0.00 - 0.00 | ESRX Avg Daily Volume: 4,187,600
Last Update: 03/22/17 - 4:00 PM EDT
Volume: 0
YTD Performance: -6.98%
Open: $0.00
Previous Close: $63.99
52 Week Range: $63.22 - $80.02
Oustanding Shares: 600,312,808
Market Cap: 38,323,969,663
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 8
Moderate Buy 0 0 0 0
Hold 8 9 9 10
Moderate Sell 0 0 0 0
Strong Sell 2 1 1 1
Mean Rec. 2.37 2.25 2.25 2.23
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 11.84
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
11.84 11.80 30.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.49% -5.23% -16.89%
Revenue -1.40 0.00 -0.01
Net Income 37.10 0.80 0.21
EPS 51.40 1.40 0.33
Earnings for ESRX:
Revenue 100.29B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.32 $1.71 $6.94 $7.62
Number of Analysts 13 11 14 13
High Estimate $1.33 $1.78 $7.01 $7.81
Low Estimate $1.31 $1.67 $6.90 $7.50
Prior Year $1.22 $1.57 $6.39 $6.94
Growth Rate (Year over Year) 8.51% 9.21% 8.64% 9.74%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

It's Time to Play Defense Real Money Pro($)

I am growing pessimistic about the market's upside potential.
Feb 25, 2015 | 6:55 AM EST
ESRX - Express Scripts Holding Co Investor Meeting - 8:30AM St. Louis, MO
Watch this leadership group that's been lagging.
Jan 28, 2015 | 6:42 AM EST
ESRX was downgraded from Outperform to Market Perform, FBR Capital Markets said. Valuation call, as the company lacks near-term catalys...

Why I'm Sticking With Biotech Real Money Pro($)

They offer a nice shelter for the headwinds now hitting equities.
Its hepatitis C drug will dominate the market.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
Here's the best way to play them.
Stocks that do well when the economy rises are shining.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.

Columnist Conversations

Panera continues to power higher today. The stock has been gaining since the early going and is now near the h...
I've been beefing up positions in Sall Beauty Holdings (SBH) shares and selling (shorting) more SBH puts to ta...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.